Pharmaceutical companies are moving their research and development (R&D) activities to the UK and US. The UK has reached an agreement with the US on zero tariffs on all medicines exported for at least three years[1]. In return, British pharmaceutical companies have pledged to invest more in the US and create jobs there[1]. The deal follows warnings from US firms to close UK branches if the NHS does not increase payments for drugs[1]. The government in London has agreed to increase investment in new medicines and treatments by around 25%, the first significant increase in more than two decades[1]. UK-based AstraZeneca has announced a five-year US$50 billion investment plan to expand research centers in Maryland and Massachusetts[2]. Switzerland's Roche has launched a similar $50 billion investment in the US for research, development and manufacturing, including a new center in Massachusetts focused on AI medicines and heart, kidney and metabolic diseases[2]. In addition, pharmaceutical giants such as AbbVie, Roche and Merck are strengthening their portfolio with acquisitions of biotech firms in the US for 1.4 to 1.5 billion USD[3].